Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $51.61 in the prior trading day, Novo Nordisk ADR (NYSE: NVO) closed at $52.56, up 1.84%. In other words, the price has increased by $1.84 from its previous closing price. On the day, 19.3 million shares were traded. NVO stock price reached its highest trading level at $53.63 during the session, while it also had its lowest trading level at $52.0.
Ratios:
Our goal is to gain a better understanding of NVO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.70. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.52.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 233549283328 and an Enterprise Value of 302180270080. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.31, and their Forward P/E ratio for the next fiscal year is 14.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.79 while its Price-to-Book (P/B) ratio in mrq is 8.73. Its current Enterprise Value per Revenue stands at 0.957 whereas that against EBITDA is 1.826.
Stock Price History:
The Beta on a monthly basis for NVO is 0.66, which has changed by -0.3984205 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $93.80, while it has fallen to a 52-week low of $43.08. The 50-Day Moving Average of the stock is 5.92%, while the 200-Day Moving Average is calculated to be -13.00%.
Shares Statistics:
The stock has traded on average 17.20M shares per day over the past 3-months and 18599250 shares per day over the last 10 days, according to various share statistics. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.03% stake in the company. Shares short for NVO as of 1765756800 were 28487274 with a Short Ratio of 1.66, compared to 1763078400 on 27691852. Therefore, it implies a Short% of Shares Outstanding of 28487274 and a Short% of Float of 0.8500000000000001.
Dividends & Splits
In the trailing 12 months, NVO’s forward annual dividend rate was 11.65, compared to 1.73 this year. Against a Trailing Annual Dividend Yield of 0.22573143. The stock’s 5-year Average Dividend Yield is 1.58. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-08-18 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts.
Analysts are recommending an EPS of between $24.69 and $22.58 for the fiscal current year, implying an average EPS of $23.03. EPS for the following year is $21.69, with 5.0 analysts recommending between $22.11 and $21.29.
Revenue Estimates
9 analysts predict $77.28B in revenue for. The current quarter. It ranges from a high estimate of $82.65B to a low estimate of $72.74B. As of. The current estimate, Novo Nordisk ADR’s year-ago sales were $85.68BFor the next quarter, 9 analysts are estimating revenue of $76.16B. There is a high estimate of $76.16B for the next quarter, whereas the lowest estimate is $76.16B.
A total of 19 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $314.87B, while the lowest revenue estimate was $302.66B, resulting in an average revenue estimate of $307.53B. In the same quarter a year ago, actual revenue was $290.4BBased on 20 analysts’ estimates, the company’s revenue will be $303.51B in the next fiscal year. The high estimate is $338.7B and the low estimate is $284.72B.
